Transition to Aging Research for Predoctoral Students (F99/K00) (RFA-AG-21-022)

Sponsor: National Institute on Aging

Award: NIA intends to commit $450,000 in FY 2021 to fund seven to 10 awards.

Due Date: October 22, 2020

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional) (RFA-AG-21-029)

Sponsor: National Institute on Aging

Award: NIA intends to commit $5.5 million in FY 2021 to support two to five awards.

Due Date: November 10, 2020. No late applications will be accepted for this Funding Opportunity Announcement.

The NINDS Human Biospecimen and Data Repository (U24 Clinical Trial Not Allowed) (RFA-NS-20-031)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: NINDS intends to commit up to $1.5 million total costs in FY 2021 to fund one award.

Due Date: October 20, 2020

Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD) (NOT-AG-20-039)

Sponsor: National Institute on Aging

CZI Deep Tissue Imaging

Sponsor: Chan Zuckerberg Initiative

Award: Awards are $1 million total costs over 2.5 years for each pilot project.

Due Date: August 6, 2020

PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) (PA-20-261)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply All applications are due by 5 p.m. local time of applicant organization.

PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) (PA-20-262)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply. All applications are due by 5 p.m. local time of applicant organization.

PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) (PA-20-265)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply. All applications are due by 5 p.m. local time of applicant organization.

Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) (PAR-20-266)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: New: October 2, 2020; June 2, 2021; October 4, 2021; June 2, 2022; October 3, 2022; June 2, 2023. Resubmissions: October 19, 2020; June 17, 2021; October 19, 2021; June 17, 2022; October 19, 2022; June 19, 2023.

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional) (PAR-20-269)

Sponsor: National Institute on Aging

Award: NIA intends to commit $5.5 million in FY 2021 to support two to five awards.

Due Date: November 10, 2020. No late applications will be accepted.

BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed) (RFA-DA-21-006)

Sponsor: National Institutes of Health

Award: Issuing IC and partner components intend to commit an estimated total of $4 million to fund two to six awards in both FY2021 and FY2022.

Due Date: October 15, 2020 and October 14, 2021.

NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional) (RFA-NS-21-001)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: The NINDS intents to commit up to $6.75 million total costs in fiscal year (FY) 2021. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: September 28, 2020, September 28, 2021, September 28, 2022. All applications are due by 5 p.m. local time of applicant organization.

NINDS Morris K. Udall Parkinson's Disease Research Center Without Walls (P20 Clinical Trial Optional) (RFA-NS-21-002)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: The NINDS intends to fund up to four awards in FY2021, corresponding to a total of $1.2 million in direct costs. Only one Exploratory Grant will be awarded per applicant institution.

Due Date: September 28, 2020. All applications are due by 5 p.m. local time of applicant organization.

PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) (PA-20-260)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply All applications are due by 5 p.m. local time of applicant organization.

Alzheimer’s Strategic Fund: Neuroimmune Program Request for Applications

Sponsor: Alzheimer's Association

Award: $150,000 - $300,000

Due Date: 5 p.m. EST on Thursday, Aug. 20, 2020